<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Angelis Consulting Group | Chandler | Activity</title>
	<link>https://angelisconsulting.com/members/combwhorl7/activity/</link>
	<atom:link href="https://angelisconsulting.com/members/combwhorl7/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Chandler.</description>
	<lastBuildDate>Thu, 06 Aug 2026 04:52:06 -0500</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">323f176ff9b22daaebf020537389c421</guid>
				<title>Chandler posted an update: Understanding the Landscape: Multiple Myeloma Lawsuits and [&#133;]</title>
				<link>https://angelisconsulting.com/activity/p/3616/</link>
				<pubDate>Tue, 04 Aug 2026 03:17:56 -0500</pubDate>

									<content:encoded><![CDATA[<p>Understanding the Landscape: Multiple Myeloma Lawsuits and Patient Safety Concerns</p>
<p>Multiple myeloma, a cancer of plasma cells in the bone marrow, remains a serious diagnosis, though developments in treatment have substantially improved survival rates over the previous twenty years. As unique therapies like immunomodulatory drugs (IMiDs),&hellip;<span class="activity-read-more" id="activity-read-more-3616"><a href="https://angelisconsulting.com/activity/p/3616/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">72edf2be52b1a2feebcfae2a81488e1b</guid>
				<title>Chandler became a registered member</title>
				<link>https://angelisconsulting.com/activity/p/3565/</link>
				<pubDate>Tue, 04 Aug 2026 02:46:16 -0500</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>